Bibliography
- MINTON NP, ATKINSON T, SHERWOOD RF: Molecular cloning of the Pseudomonas carboxypeptidase G2 gene and its expression in Escherichia coil and pseudomonaspudda. J. Bacteriol (1983) 156:1222–1227.
- ROWSELL S, PAUPTIT RA, TUCKER AD, MELTON RG, BLOW DM, BRICK P: Crystal structure of carboxypepti-dase G2, a bacterial enzyme with applications in cancer therapy. Structure (1997) 5:337–347.
- SHERWOOD RF, MELTON RG, ALWAN SM, HUGHES P:Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS16. Eur. J. Biochem (1985) 148:447–453.
- DEANGELIS LM, TANG WP, SILAN L, FLEISHER M,BERTINO JR: Carboxypeptidase G2 rescue after high-dose methotrexate. J. Clin. Oncol. (1996) 14:2145–2149.
- BURKE PJ: The design and synthesis of prodrugs for antibody-directed enzyme prodrug therapy. In: Enzyme-Prodrug Strategies for Cancer Therapy. Melton RG and Knox RJ (Eds.), Kluwer Academic/Plenum Publishers, New York, USA (1999):133–154.
- BAGSHAWE KD, NAPIER M: Early Clinical Studies with ADEPT. In:Enzyme-Prodrug Strategies for Cancer Therapy. Melton RG and Knox RJ (Ed.), Kluwer Academic/Plenum Publishers, New York (1999):199–207.
- •Demonstrates the practicability of ADEPT in a clinical setting.
- KHAN TH, ENO-AMOOQUAYE E, SEARLE F, BROWNE PJ, OSBORN HMI, BURKE PJ: Novel inhibitors of carboxypeptidase G2 (CPG2): potential for use in antibody-directed enzyme prodrug therapy (ADEPT). J. Med. Chem. (1999) 42:951–956.
- DUNCAN R, DIMIYTRIJEVIC S, EVAGOROU EG: The role of polymer conjugates in the diagnosis and treatment of cancer. STP Pharma Sciences (1996) 6:237–263.
- VASEY PA, KAYE SB, MORRISON R et al: Phase I clinicaland pharmacokinetic study of PK1 [N-(2- hydroxy-propyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents -drug-polymer conjugates. Cancer Research Campaign Phase I/II committee. Clin. Can. Res. (1999) 5:83–94.
- BLAKEY DC, DAVIES DH, DOWELL RI eta].: Anti-tumoureffects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs. Br. J. Cancer (1995) 72:1083–1088.
- KAYE SB. New antimetabolites in cancer chemotherapy and their clinical impact. Br. J. Cancer (1998) 78:1–7.
- BAGSHAWE KD, BURKE PJ, KNOX RJ, MELTON RG, SHARMA SK: Targeting enzymes to cancers - new developments. Exp. Opin. Invest. Drugs (1999) 8:161–172.
- MARAIS R, SPOONER RA, LIGHT Y, MARTIN J, SPRINGER CJ: Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Research (1996) 56:4735–4742.
- NICULESCU-DUVAZ I, SPRINGER CJ: Gene-directed enzyme prodrug therapy (GDEPT); a review of enzyme/prodrug combinations. Exp. Opin. Invest. Drugs (1997) 6:685–703.
- SPRINGER CJ, NICULESCU-DUVAZ I: Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs. AntiCancer Drug Design (1995) 10:361–372.
- MARAIS R, SPOONER RA, STRIBBLING SM, LIGHT Y, MARTIN J, SPRINGER CJ: A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy. Nature Biotechnology (1997) 15:1373–1377.
- •This article describes a novel approach to delivering an enzyme to tumour sites for prodrug activation.
- NICULESCU-DUVAZ I, NICULESCU-DUVAZ D, FRIEDLOS F et al.: Self-immolative prodrugs for suicide gene therapy. J. Med. Chem. (1999) 32:2485–2489.